Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:MBII

Marrone Bio Innovations (MBII) Stock Price, News & Analysis

Marrone Bio Innovations logo

About Marrone Bio Innovations Stock (NASDAQ:MBII)

Key Stats

Today's Range
$0.80
$0.80
50-Day Range
$0.80
$0.80
52-Week Range
$0.55
$1.55
Volume
38 shs
Average Volume
919,497 shs
Market Capitalization
$145.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects. The company also offers Regalia and Stargus, which protects against fungal and bacterial diseases and enhances yields/quality; Venerate, a bioinsecticide that controls chewing and sucking insects and mites; and Zelto, a bionematicide that protects turf, including golf course fairways and greens, and promotes turf health by enhancing plant and root health. It provides its products directly through sales force, as well as through distributors and other commercial partners. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was incorporated in 2006 and is headquartered in Raleigh, North Carolina.

Receive MBII Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marrone Bio Innovations and its competitors with MarketBeat's FREE daily newsletter.

MBII Stock News Headlines

Upstream Bio Inc
Upstream Bio Inc (UPB)
Your chance to get on the next “60-Second Trade”
Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!
Man shot, killed by Olive Branch SWAT team
See More Headlines

MBII Stock Analysis - Frequently Asked Questions

Marrone Bio Innovations, Inc. (NASDAQ:MBII) released its earnings results on Wednesday, November, 10th. The basic materials company reported ($0.03) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.03). The basic materials company had revenue of $9.86 million for the quarter, compared to analysts' expectations of $10.79 million. Marrone Bio Innovations had a negative net margin of 47.07% and a negative trailing twelve-month return on equity of 70.87%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Marrone Bio Innovations investors own include ObsEva (OBSV), Amyris (AMRS), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Rexahn Pharmaceuticals (REXN), Plug Power (PLUG) and Denali Therapeutics (DNLI).

Company Calendar

Last Earnings
11/10/2021
Today
12/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Agricultural Chemicals
Sub-Industry
N/A
Current Symbol
NASDAQ:MBII
Fax
N/A
Employees
153
Year Founded
N/A

Profitability

Net Income
$-16,550,000.00
Pretax Margin
-47.12%

Debt

Sales & Book Value

Annual Sales
$44.31 million
Book Value
$0.17 per share

Miscellaneous

Free Float
173,259,000
Market Cap
$145.56 million
Optionable
Not Optionable
Beta
0.36

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

This page (NASDAQ:MBII) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners